StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Oppenheimer on Allogene (ALLO): 'data represents strong early validation of the ALPHA3 strategy'
April 13, 2026 12:04 PM
Oppenheimer analyst Matt Biegler reiterated an Outperform rating and $7.00 price target on Allogene (NASDAQ: ALLO)The analyst commented, "Allogene reported ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
